Webinar: Addressing Three Clinical Questions in Diabetes (CSEM)

Duration

1 hr

Profession

Specialist

# of Credits

1.0

Accreditation

MOC - Section 1

Expiry Date

2023-07-12

The evidence regarding the management of type 2 diabetes is continually evolving. As this evidence evolves, there are issues that arise where the clinician can consider multiple pathways for the management of patients. Three issues that are currently being debated will be addressed within this webinar. It will review the evidence supporting diabetes remission at diagnosis versus regulation, the debate of glycemic control versus cardiovascular risk reduction and the role of continuous glucose monitoring as a potentially preferred method of monitoring over HbA1c measurement. The international expert panel will review the current evidence and share their insight on each of these issues so that their colleagues can integrate the evidence into their clinical practice.


This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.

This activity is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program, recognized in Europe by the European Accreditation Council for Continuing Medical Education and accredited by the Saudi Commission for Health Specialties for up 1.0 CPD.

Credits are reported to the Saudi Commission for Health Specialties on a monthly basis. Please ensure that your Saudi Commission ID is accurate in your profile and allow sufficient time for credits to appear in your Mustamir account.

N/A

David Strain, BSc(Hons), MB. ChB., MRCP(UK), MD, FRCP(London)
Matthias Blüher, MD
Alice Cheng, MD
Celine Huot, MD, FRCPC
Roopa Mehta, MBBS, MRCP
Saud Al Sifri, MD, FACE

Upon successful completion of this continuing education module, the participant will be better able to:

  • Discuss the evidence for remission of diabetes
  • Initiate diabetes treatment in newly-diagnosed patients with type 2 diabetes, according to the Diabetes Canada guidelines
  • Start a conversation with patients to enable shared decision making for treatment initiation
  • Individualize treatment according to patient concerns and priorities